EQ Equillium, Inc.
NEUTRAL
Impact: 3/10
PRESS-RELEASE
Press release: fda
Latest settled — T+5d
EQ ▲ +28.51% at T+5d
NEUTRAL call ✓ call won +28.51% · α vs SPY +26.91% · entry $2.21 → $2.84
Currently $2.70 · +22.17% from $2.21 entry
T+1d
+2.26%
call +2.26% · α +1.82%
$2.26
settled 20d ago
T+5d
+28.51%
call +28.51% · α +26.91%
$2.84
settled 13d ago
T+20d
—
call — · α —
—
in 8d
T+60d
—
call — · α —
—
in 2mo
Price Chart
Loading chart...
Executive Summary
Equillium announced a virtual investor event on May 27, 2026, to present new preclinical data on AhR modulators and the AhR/miR-124 axis. No clinical results were disclosed; the event is a research update that may provide insight into the mechanism of EQ504. The announcement is non-material without data.
Actionable Insight
Monitor the May 27 event for data releases that could inform EQ504's development trajectory. Until then, no near-term catalyst is present.
Key Facts
- Virtual investor event scheduled for May 27, 2026, 11:00 AM ET.
- Event will feature new preclinical data on AhR modulators and the relationship between AhR activation and miR-124 induction.
- EQ504 is an investigational AhR modulator for ulcerative colitis and inflammatory lung diseases.
- The company seeks to resolve a paradoxical relationship between AhR and miR-124 that has remained controversial.
Financial Impact
No financial impact disclosed.
Risk Factors
- Preclinical data may not translate to clinical success.
- Conflict with published studies could limit mechanistic confidence.
- No timeline for clinical trials or regulatory milestones provided.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298855 |
7 reports for EQ
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
Insider Cluster
| $3.12 awaiting T+5 | awaiting T+5 | — | $2.70 (+13.46%) |
|
May 29, 2026
11d ago
|
Insider Cluster
| $3.08 $2.94 | ▼ −4.55% | ▼ −1.80% | $2.70 (−12.34%) |
|
May 20, 2026
20d ago
|
Press Release
| $2.21 $2.84 | ▲ +28.51% | ▲ +26.91% | $2.70 (+22.17%) |
|
Apr 17, 2026
7w ago
|
EFFECT
| $2.05 $2.16 | ▲ +5.37% | ▲ +4.81% | $2.70 (+31.71%) |
|
Apr 15, 2026
7w ago
|
DEFA14A
| $2.05 $2.33 | ▲ +13.66% | ▲ +12.02% | $2.70 (+31.71%) |
|
Apr 7, 2026
9w ago
|
S-3
| $1.80 $2.05 | ▲ +13.89% | ▲ +10.37% | $2.70 (+50.00%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $2.06 $1.97 | ▲ +4.37% | ▲ +6.00% | $2.70 (−31.07%) |
Showing 7 of 7
US Market Status
Market Closed — Opens Thu (10h 13m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access